摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(3-nitrophenyl)methylene]-3-oxobutanoic acid,1-methylethyl ester | 118431-79-1

中文名称
——
中文别名
——
英文名称
2-[(3-nitrophenyl)methylene]-3-oxobutanoic acid,1-methylethyl ester
英文别名
2-<(3-nitrophenyl)methylene>-3-oxobutanoic acid 1-methylethyl ester;isopropyl (Z)-2-(3-nitrobenzylidene)-3-oxobutanoate;isopropyl 2-(3-nitrobenzylidene)-acetoacetate;3'-nitrobenzylideneacetoacetic acid isopropyl ester;2-[(3-nitrophenyl)methylene]-3-oxobutanoic acid, 1-methylethyl ester;3-nitrobenzylideneacetoacetic acid isopropyl ester;Isopropyl 2-(3-nitrobenzylidene)acetoacetate;propan-2-yl (2Z)-2-[(3-nitrophenyl)methylidene]-3-oxobutanoate
2-[(3-nitrophenyl)methylene]-3-oxobutanoic acid,1-methylethyl ester化学式
CAS
118431-79-1
化学式
C14H15NO5
mdl
——
分子量
277.277
InChiKey
KSZOTXZFYCRWQK-JYRVWZFOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    92 °C(Solv: isopropanol (67-63-0))
  • 沸点:
    404.9±35.0 °C(Predicted)
  • 密度:
    1.229±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    89.2
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05202330A1
    公开(公告)日:1993-04-13
    Pyrimidine compounds of the formula ##STR1## wherein X is sulfur or oxygen, Y is R.sub.11 or --O--R.sub.1, and R.sub.4 is aryl or heterocyclo are disclosed. These compounds are useful as cardiovascular agents, particularly anti-hypertensive agents, due to their calcium entry blocking vasodilator activity.
    公开了符合以下公式的嘧啶化合物##STR1##其中X是硫或氧,Y是R.sub.11或--O--R.sub.1,R.sub.4是芳香族或杂环。这些化合物由于其钙通道阻滞血管扩张剂活性而被用作心血管药物,特别是抗高血压药物。
  • 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US04855301A1
    公开(公告)日:1989-08-08
    Cardiovascular activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein X is oxygen or sulfur; R is hydrogen, alkyl, cycloalkyl, aryl, or arylalkyl and R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR2## or halo substituted alkyl, or R and R.sub.1 taken together with the nitrogen atom to which they are attached are 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl or 1-pyrrolidinyl, 1-piperidinyl, or 1-azeipinyl substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy; R.sub.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, ##STR3## or halo substituted alkyl; R.sub.3 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR4## or halo substituted alkyl; R.sub.4 is aryl or heterocyclo; R.sub.5 and R.sub.6 are each independently hydrogen, alkyl, --(CH.sub.2).sub.q --aryl or --(CH.sub.2).sub.q --cycloalkyl; Y.sub.1 is cycloalkyl, aryl, heterocyclo, hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, amino, substituted amino, carbamoyl, ##STR5## Y.sub.3 is hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, ##STR6## amino, or substituted amino; q is 0, 1, 2 or 3; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 5; and p is an integer of 1 to 5.
    心血管活性化合物具有以下通式: ##STR1## 及其药学上可接受的盐,其中X为氧或硫;R为氢、烷基、环烷基、芳基或芳基烷基,R1为氢、烷基、环烷基、芳基、杂环、##STR2##或卤代烷基,或者R和R1与其所连接的氮原子一起形成1-吡咯烷基、1-哌啶基、1-氮杂环庚三烯基、4-吗啉基、4-硫吗啉基、1-哌嗪基、4-烷基-1-哌嗪基、4-芳基烷基-1-哌嗪基、4-二芳基烷基-1-哌嗪基或1-吡咯烷基、1-哌啶基、或1-氮杂环庚三烯基,这些基团可以被烷基、烷氧基、烷硫基、卤素、三氟甲基或羟基取代;R2为氢、烷基、烯基、炔基、环烷基、芳基、##STR3##或卤代烷基;R3为氢、烷基、环烷基、芳基、杂环、##STR4##或卤代烷基;R4为芳基或杂环;R5和R6各自独立为氢、烷基、--(CH2)q--芳基或--(CH2)q--环烷基;Y1为环烷基、芳基、杂环、羟基、烷氧基、芳基--(CH2)m--O--、巯基、烷硫基、芳基--(CH2)m--S--、氨基、取代氨基、氨基甲酰基、##STR5##Y3为羟基、烷氧基、芳基--(CH2)m--O--、巯基、烷硫基、芳基--(CH2)m--S--、##STR6##氨基或取代氨基;q为0、1、2或3;m为0或1至6的整数;n为0或1至5的整数;p为1至5的整数。
  • Polymorph Compositions, Methods of Making, and Uses Thereof
    申请人:Macdonald R. Loch
    公开号:US20130302431A1
    公开(公告)日:2013-11-14
    The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
    所述发明提供了一种可生物降解、生物相容的流动持续释放微粒组合物的输送系统,其包含一种基本纯的晶体形式的生物活性剂,例如尼莫地平,以及一种制备基本纯的晶体形式生物活性剂的治疗形式的过程,以及一种治疗哺乳动物脑损伤引起的潜在中断的蛛网膜下腔脑动脉中断的方法,该方法减少与脑损伤相关的至少一种延迟并发症的症状或体征。
  • Synthesis of Unsymmetrically Substituted 1,4-Dihydropyridines and Analogous Calcium Antagonists by Microwave Heating
    作者:Ramón Alajarin、Pilar Jordán、Juan J. Vaquero、Julio Alvarez-Builla
    DOI:10.1055/s-1995-3933
    日期:1995.4
    Rapid and efficient synthesis of 3,5-unsymmetrically substituted 1,4-dihydropyridines and imidazopyrimidine derivatives can be achieved under microwave irradiation using a household microwave oven.
    利用家用微波炉,在微波辐照下可快速高效地合成 3,5 不对称取代的 1,4 二氢吡啶和咪唑嘧啶衍生物。
  • Enantioselective hantzsch dihydropyridine synthesis via metalated chiral alkyl acetoacetate hydrazones1
    作者:Dieter Enders、Stephan Müller、Ayhan S. Demir
    DOI:10.1016/s0040-4039(00)82366-7
    日期:1988.1
    An efficient, overall enantioselective variant of the Hantzsch synthesis of 4-aryl-1,4-dihydropyridines (ee = 84 - 98%), important biologically active compounds (e. g. as calcium channel blockers), is described. Key step of the new procedure is the asymmetric Michael addition of metalated chiral alkyl acetoacetate hydrazones ()- to the Knoevenagel acceptors . An accurate method to determine the enantiomeric
    描述了4-芳基-1,4-二氢吡啶(ee = 84-98%)(重要的生物活性化合物(例如,作为钙通道阻滞剂))的汉茨合成的有效的整体对映选择性变体。新方法的关键步骤是将金属化手性烷基乙酰乙酸()-不对称迈克尔加成到Knoevenagel受体上。还报道了确定手性二氢吡啶的对映体过量的准确方法。
查看更多